Søren Christensen

Søren Christensen

Auto-generated profile, based on publicly available information

Søren Christensen

Department of Biotherapeutic Discovery, H. Lundbeck A/S, Copenhagen, Denmark

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 March 2019 in Scientific Reports
Verified
Journal Article
Open access
PDF file
CAChristian Rungsted Andersson
Christian Rungsted Andersson
JFJeppe Falsig
Jeppe Falsig
JSJeffrey B. Stavenhagen
Jeffrey B. Stavenhagen
SCSøren Christensen
Søren Christensen
FKFredrik Kartberg
Fredrik Kartberg
JPJan Torleif Pedersen
Jan Torleif Pedersen
Neurodegenerative diseases such as Alzheimer’s disease are characterized by the progressive spreading and accumulation of hyper-phosphorylated tau protein in the brain. Anti-tau antibodies have been shown to reduce tau pathology in in vivo models and antibody-mediated clearance of tau exerted by microglia has been proposed as a contributing factor. By subjecting primary microglia cultured in vitro to anti-phospho-tau antibodies in complex with pathological tau, we show that microglia internalise and degrade tau in a manner that is dependent on FcγR interaction and functional lysosomes. It has recently been discussed if anti-tau antibody effector-functions are required for induction of tau clearance. Using antibodies with compromised FcγR binding and non-compromised control antibodies we show that antibody effector functions are required for induction of microglial clearance of tau. Understanding the inflammatory consequences of targeting microglia using therapeutic antibodies is important when developing these molecules for clinical use. Using RNA sequencing, we show that treatment with anti-tau antibodies increases transcription of mRNA encoding pro-inflammatory markers, but that the mRNA expression profile of antibody-treated cells differ from the profile of LPS activated microglia. We further demonstrate that microglia activation alone is not sufficient to induce significant tau clearance.

7 June 2017 in Molecular Neurodegeneration
Verified
Journal Article
Open access
PDF file
TBTomasz Brudek
Tomasz Brudek
KWKristian Winge
Kristian Winge
JFJonas Folke
Jonas Folke
SCSøren Christensen
Søren Christensen
KFKarina Fog
Karina Fog
LPLars Østergaard Pedersen
Lars Østergaard Pedersen
Parkinson’s’ disease (PD) and Multiple System Atrophy (MSA) are progressive brain disorders characterized by intracellular accumulations of α-synuclein and nerve cell loss in specific brain areas. This loss causes problems with movement, balance and/or autonomic functions. Naturally occurring autoantibodies (NAbs) play potentially an important role in clearing or/and blocking circulating pathological proteins. Little is known about the functional properties of anti-α-synuclein NAbs in PD and MSA, and there have been opposing reports regarding their plasma concentrations in these disorders. We have investigated the apparent affinity of anti-α-synuclein NAbs in plasma samples from 46 PD patients, 18 MSA patients and 41 controls using competitive enzyme-linked immunosorbent assay (ELISA) and Meso Scale Discovery (MSD) set-ups. We found that the occurrence of high affinity anti-α-synuclein NAbs in plasma from PD patients is reduced compared to healthy controls, and nearly absent in plasma from MSA patients. Also, levels of α-synuclein/NAbs immunocomplexes is substantially reduced in plasma from both patient groups. Further, cross binding of anti-α-synuclein NAbs with β- and γ-synuclein monomers suggest, the high affinity anti-α-synuclein plasma component, seen in healthy individuals, is directed mainly against C-terminal epitopes. Furthermore, we also observed reduced occurrence of high affinity anti-phosphorylated-α-synuclein NAbs in plasma from PD and MSA patients. One interpretation implies that these patients may have impaired ability to clear and/or block the effects of pathological α-synuclein due to insufficient/absent concentration of NAbs and as such provides a rationale for testing immune-based therapeutic strategies directed against pathological α-synuclein. Following this interpretation, we can hypothesize that high affinity autoantibodies efficiently bind and clear potentially pathological species of α-synuclein in healthy brain, and that this mechanism is impaired or absent in PD and MSA patients.

1 January 2018 in Alzheimer's & Dementia: Translational Research & Clinical Interventions
Verified
Journal Article
Open access
NRNina Rosenqvist
Nina Rosenqvist
AAAyodeji A. Asuni
Ayodeji A. Asuni
CAChristian R. Andersson
Christian R. Andersson
SCSøren Christensen
Søren Christensen
JDJustus A. Daechsel
Justus A. Daechsel
JPJan T. Pedersen
Jan T. Pedersen
Introduction: The abnormal hyperphosphorylation of the microtubule‐associated protein tau plays a crucial role in neurodegeneration in Alzheimer's disease (AD) and other tauopathies. Methods: Highly specific and selective anti‐pS396‐tau antibodies have been generated using peptide immunization with screening against pathologic hyperphosphorylated tau from rTg4510 mouse and AD brains and selection in in vitro and in vivo tau seeding assays. Results: The antibody C10.2 bound specifically to pS396‐tau with an IC 50 of 104 pM and detected preferentially hyperphosphorylated tau aggregates from AD brain with an IC 50 of 1.2 nM. C10.2 significantly reduced tau seeding of P301L human tau in HEK293 cells, murine cortical neurons, and mice. AD brain extracts depleted with C10.2 were not able to seed tau in vitro and in vivo, demonstrating that C10.2 specifically recognized pathologic seeding‐competent tau. Discussion: Targeting pS396‐tau with an antibody like C10.2 may provide therapeutic benefit in AD and other tauopathies.

6 August 2015 in Analytical Chemistry
Verified
Journal Article
Closed access
ETEsben Trabjerg
Esben Trabjerg
RJRasmus U. Jakobsen
Rasmus U. Jakobsen
SMSimon Mysling
Simon Mysling
SCSøren Christensen
Søren Christensen
TJThomas J. D. Jørgensen
Thomas J. D. Jørgensen
KRKasper D. Rand
Kasper D. Rand

25 August 2018 in Annals of Neurology
Verified
Journal Article
Closed access
PDF file
LGLamia Ghezali
Lamia Ghezali
CCCarmen Capone
Carmen Capone
CBCéline Baron‐Menguy
Céline Baron‐Menguy
JRJulien Ratelade
Julien Ratelade
SCSøren Christensen
Søren Christensen
AJAnne Joutel
Anne Joutel

3 October 2015 in Acta Neuropathologica
Verified
Journal Article
Open access
PDF file
JFJames P. Fuller
James P. Fuller
JSJeffrey B. Stavenhagen
Jeffrey B. Stavenhagen
SCSøren Christensen
Søren Christensen
FKFredrik Kartberg
Fredrik Kartberg
MGMartin J. Glennie
Martin J. Glennie
JTJessica L. Teeling
Jessica L. Teeling
Immunotherapy is a promising strategy for the treatment of Alzheimer’s disease (AD). Antibodies directed against Amyloid Beta (Aβ) are able to successfully clear plaques and reverse cognitive deficits in mouse models. Excitement towards this approach has been tempered by high profile failures in the clinic, one key issue has been the development of inflammatory side effects in the brain (ARIAs). New antibodies are entering the clinic for Alzheimer’s disease; therefore, it is important to learn all we can from the current generation. In this study, we directly compared 3 clinical candidates in the same pre-clinical model, with the same effector function, for their ability to clear plaques and induce inflammation in the brain. We produced murine versions of the antibodies: Bapineuzumab (3D6), Crenezumab (mC2) and Gantenerumab (chGantenerumab) with an IgG2a constant region. 18-month transgenic APP mice (Tg2576) were injected bilaterally into the hippocampus with 2 µg of each antibody or control. After 7 days, the mice tissue was analysed for clearance of plaques and neuroinflammation by histology and biochemical analysis. 3D6 was the best binder to plaques and in vitro, whilst mC2 bound the least strongly. This translated into 3D6 effectively clearing plaques and reducing the levels of insoluble Aβ, whilst chGantenerumab and mC2 did not. 3D6 caused a significant increase in the levels of pro-inflammatory cytokines IL-1β and TNFα, and an associated increase in microglial expression of CD11B and CD68. chGantenerumab increased pro-inflammatory cytokines and microglial activation, but minimal changes in CD68, as an indicator of phagocytosis. Injection of mC2 did not cause any significant inflammatory changes. Our results demonstrate that the ability of an antibody to clear plaques and induce inflammation is dependent on the epitope and affinity of the antibody.